Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2

Oncotarget

Volumn 6, Issue 32, 2015, Pages 32856-32867

  Pandiella, Atanasio ^a   Morís, Francisco ^b   Ocaña, Alberto ^c   Núñez, Luz Elena ^b   Montero, Juan C ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Campus El Cristo   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

Cell cycle; EC 8042; Mithralogs; Triple negative breast cancer

Indexed keywords

CARBOPLATIN; DACTOLISIB; DASATINIB; DEMYCAROSIL 3D BETA DEXTRO DIGITOXOSYL; DOCETAXEL; GEMCITABINE; MITHRAMYCIN; NAVELBINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CASPASE; CDK1 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; DEMYCAROSYL-3D-DIGITOXOSYLMITHRAMYCIN SK; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; TAXOID; WEE1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; DRUG SAFETY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TRIPLE NEGATIVE BREAST CANCER; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; IC50; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; INHIBITORY CONCENTRATION 50; MICE, INBRED BALB C; MICE, NUDE; NUCLEAR PROTEINS; PHOSPHORYLATION; PLICAMYCIN; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TAXOIDS; TIME FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946048469     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5942     Document Type: Article

References (33)

1. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007; 8: 235-244.
2. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011; 16 Suppl 1: 1-11.
3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-5374.
4. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010; 7: 683-692.
5. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Jr., Ellis P, Di Leo A, Baselga J, Sotiriou C et al. Dissecting the Heterogeneity of Triple-Negative Breast Cancer. J Clin Oncol. 2012; 30: 1879-1887.
6. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13: 4429-4434.
7. Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res. 2010; 12: R41.
8. Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by highthroughput screening. J Natl Cancer Inst. 2011; 103: 962-978.
9. Zhang M, Mathur A, Zhang Y, Xi S, Atay S, Hong JA, Datrice N, Upham T, Kemp CD, Ripley RT, Wiegand G, Avital I, Fetsch P et al. Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells. Cancer Res. 2012; 72: 4178-4192.
10. ClinicalTrials.gov. NCT01610570 and NCT01624090.
11. Remsing LL, Gonzalez AM, Nur-e-Alam M, FernandezLozano MJ, Brana AF, Rix U, Oliveira MA, Mendez C, Salas JA, Rohr J. Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis. J Am Chem Soc. 2003; 125: 5745-5753.
12. Barcelo F, Scotta C, Ortiz-Lombardia M, Mendez C, Salas JA, Portugal J. Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences. Nucleic Acids Res. 2007; 35: 2215-2226.
13. Barcelo F, Ortiz-Lombardia M, Martorell M, Oliver M, Mendez C, Salas JA, Portugal J. DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis. Biochemistry. 2010; 49: 10543-10552.
14. Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, Kwee I, Nur-e-Alam M, Bergant J, Bertoni F, Carbone GM, Rohr J, Catapano CV. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res. 2006; 34: 1721-1734.
15. Previdi S, Malek A, Albertini V, Riva C, Capella C, Broggini M, Carbone GM, Rohr J, Catapano CV. Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecol Oncol. 2010; 118: 182-188.
16. Jia Z, Zhang J, Wei D, Wang L, Yuan P, Le X, Li Q, Yao J, Xie K. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res. 2007; 67: 4878-4885.
17. Vizcaino C, Mansilla S, Nuñez LE, Mendez C, Salas JA, Moris F, Portugal J. Novel mithramycins abrogate the involvement of protein factors in the transcription of cell cycle control genes. Biochem Pharmacol. 2012; 84: 1133-1142.
18. Tagashira M, Kitagawa T, Isonishi S, Okamoto A, Ochiai K, Ohtake Y. Mithramycin represses MDR1 gene expression in vitro, modulating multidrug resistance. Biol Pharm Bull. 2000; 23: 926-929.
19. Méndez C, González-Sabín J, Morís F, Salas J. Expanding the chemical diversity of the antitumor mithramycin by combinatorial biosynthesis and biocatalysis: the quest for mithralogs with improved therapeutic window. Planta Medica 2015; In press.
20. Nuñez LE, Nybo SE, Gonzalez-Sabin J, Perez M, Menendez N, Brana AF, Shaaban KA, He M, Moris F, Salas JA, Rohr J, Mendez C. A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis. J Med Chem. 2012; 55: 5813-5825.
21. Vizcaino C, Nuñez LE, Moris F, Portugal J. Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue. PLoS One. 2014; 9: e104687.
22. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009; 8: 547-566.
23. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22: 27-55.
24. McGowan CH, Russell P. Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J. 1993; 12: 75-85.
25. Atherton-Fessler S, Liu F, Gabrielli B, Lee MS, Peng CY, Piwnica-Worms H. Cell cycle regulation of the p34cdc2 inhibitory kinases. Mol Biol Cell. 1994; 5: 989-1001.
26. Korner K, Wolfraim LA, Lucibello FC, Muller R. Characterization of the TATA-less core promoter of the cell cycle-regulated cdc25C gene. Nucleic Acids Res. 1997; 25: 4933-4939.
27. Fernandez-Guizan A, Mansilla S, Barcelo F, Vizcaino C, Nunez LE, Moris F, Gonzalez S, Portugal J. The activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription. Chem Biol Interact. 2014; 219: 123-132.
28. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10: 515-527.
29. Cabrera N, Diaz-Rodriguez E, Becker E, Martin-Zanca D, Pandiella A. TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment. J Cell Biol. 1996; 132: 427-436.
30. Yuste L, Montero JC, Esparis-Ogando A, Pandiella A. Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin. Cancer Res. 2005; 65: 6801-6810.
31. Montero JC, Chen X, Ocana A, Pandiella A. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Mol Cancer Ther. 2012; 11: 1342-1352.
32. Montero JC, Esparis-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocana A, Pandiella A. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene. 2014; 33: 148-156.
33. Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernandez S, San-Segundo L, Vilanova D, Lopez-Corral L, Montero JC, Hernandez-Iglesias T, de Alava E, Galmarini C, Aviles P et al. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood. 2009; 113: 3781-3791.